Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia.
Very low density lipoprotein overproduction is the major metabolic characteristic in familial combined hyperlipidemia (FCHL). Peripheral handling of free fatty acids (FFAs) in vitro may be impaired in FCHL by decreased action of acylation-stimulating protein (ASP), which is identical to the immunologically inactive complement component 3a (C3adesArg). Because decreased FFA uptake by impaired complement component 3 (C3) response (as the precursor for ASP) may result in enhanced FFA flux to the liver in FCHL, we have evaluated postprandial C3 changes in vivo in FCHL patients. Accordingly, 10 untreated FCHL patients and 10 matched control subjects underwent an oral fat loading test. Fasting plasma C3 and ASP levels were higher in FCHL patients (1.33+/-0.09 g/L and 70.53+/-4.37 mmol/L, respectively) than in control subjects (0.91+/-0.03 g/L and 43.21+/-8.96 mmol/L, respectively; P=0.01 and P<0.05). In control subjects, C3 concentrations increased significantly after 4 hours (to 1.03+/-0.04 g/L). In FCHL, plasma C3 was unchanged after 4 hours. The earliest postprandial C3 rise in FCHL patients occurred after 8 hours (1.64+/-0.12 g/L). The maximal apolipoprotein B-48 concentration was reached after 6 hours in FCHL patients and control subjects. Postprandial FFA and hydroxybutyric acid (as a marker of hepatic FFA oxidation) were significantly higher in FCHL patients than in control subjects, and the early postprandial C3 rise was negatively correlated with the postprandial FFA and hydroxybutyric acid concentrations. The present data suggest an impaired postprandial plasma C3 response in FCHL patients, most likely as a result of a delayed response by C3, as the precursor for the biologically active ASP, acting on FFA metabolism. Therefore, an impaired postprandial C3 response may be associated with impaired peripheral postprandial FFA uptake and, consequently, lead to increased hepatic FFA flux and very low density lipoprotein overproduction.
Meijssen
S
S
Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
van Dijk
H
H
Verseyden
C
C
Erkelens
D W
DW
Cabezas
M Castro
MC
D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D002561:Cerebrovascular Disorders / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D003176:Complement C3 / Q000378:metabolism*; D015926:Complement C3a / Q000031:analogs & derivatives*; D004041:Dietary Fats / Q000378:metabolism; D005215:Fasting / Q000097:blood / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D006950:Hyperlipidemia, Familial Combined / Q000097:blood*; D006949:Hyperlipidemias / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000097:blood; D019518:Postprandial Period / Q000502:physiology*; D014280:Triglycerides / Q000097:blood
D001798:Blood Proteins; D002914:Chylomicrons; D003176:Complement C3; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D014280:Triglycerides; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a